Literature DB >> 35064360

Circ-ATIC Serves as a Sponge of miR-326 to Accelerate Esophageal Squamous Cell Carcinoma Progression by Targeting ID1.

Bing Zhang1, Weiwei Chu1, Zhe Li1, Yaxiao Zhang1, Qiang Zhen1, Baolei Lv1, Jiabao Liu1, Caiping Lu2, Xiaojian Zhao3.   

Abstract

In the previous studies, circular RNA (circRNA) has been shown to be closely related to the occurrence and development of various cancers. However, the role and mechanism of circ-ATIC in the progression of esophageal squamous cell carcinoma (ESCC) is not yet clear. Quantitative real-time PCR was used to detect the expression levels of circ-ATIC, microRNA (miR)-326 and inhibitor of DNA binding 1 (ID1) in tissues (n = 50) and cells. Cell counting kit 8 assay, colony formation assay, flow cytometry, wound-healing assay and transwell assay were performed to measure the proliferation, apoptosis, migration, and invasion of cells. In addition, the oxidative stress of cells was evaluated by detecting the productions of superoxide dismutase and malondialdehyde. Animal studies were implied to explore the role of circ-ATIC in ESCC tumor growth. The relationship between circ-ATIC and miR-326 or ID1 was determined by dual-luciferase reporter assay and RNA immunoprecipitation assay. Additionally, the protein expression of ID1 was examined by western blot assay. Circ-ATIC was found to be upregulated in ESCC tissues and cells. Silenced circ-ATIC suppressed the proliferation, migration, invasion, promoted the apoptosis and oxidative stress of ESCC cells. The tumor growth of ESCC also was inhibited by circ-ATIC knockdown. Furthermore, we found that circ-ATIC could sponge miR-326, and miR-326 could target ID1. The rescue experiments revealed that miR-326 inhibitor could reverse the negative regulation of circ-ATIC silencing on ESCC progression, and ID1 overexpression also inverted the inhibitory effect of miR-326 on ESCC progression. In addition, we confirmed that the expression of ID1 was positively regulated by circ-ATIC. Our study showed that circ-ATIC facilitated the progression of ESCC by regulating the miR-326/ID1 axis, indicating that circ-ATIC might be a target for ESCC treatment.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Circ-ATIC; Esophageal squamous cell carcinoma; ID1; miR-326

Mesh:

Substances:

Year:  2022        PMID: 35064360     DOI: 10.1007/s10528-021-10167-3

Source DB:  PubMed          Journal:  Biochem Genet        ISSN: 0006-2928            Impact factor:   2.220


  31 in total

Review 1.  Regulation of circRNA biogenesis.

Authors:  Ling-Ling Chen; Li Yang
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

Review 2.  Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy.

Authors:  Hidekazu Hirano; Ken Kato
Journal:  Jpn J Clin Oncol       Date:  2019-05-01       Impact factor: 3.019

3.  Exosomes secreted from mesenchymal stem cells mediate the regeneration of endothelial cells treated with rapamycin by delivering pro-angiogenic microRNAs.

Authors:  Weizong Wang; Yixin Zhao; Huilin Li; Yujiao Zhang; Xiaomeng Jia; Cong Wang; Pengju Zhu; Jiangrong Wang; Yinglong Hou
Journal:  Exp Cell Res       Date:  2020-12-19       Impact factor: 3.905

Review 4.  Circular RNAs: analysis, expression and potential functions.

Authors:  Steven P Barrett; Julia Salzman
Journal:  Development       Date:  2016-06-01       Impact factor: 6.868

5.  Nomogram to Predict Overall Survival for Thoracic Esophageal Squamous Cell Carcinoma Patients After Radical Esophagectomy.

Authors:  Wei Deng; Wencheng Zhang; Jinsong Yang; Wenjie Ni; Shufei Yu; Chen Li; Xiao Chang; Zongmei Zhou; Dongfu Chen; Qinfu Feng; Xiaohui Chen; Yu Lin; Kunshou Zhu; Xiongwei Zheng; Jie He; Shugeng Gao; Qi Xue; Yousheng Mao; Guiyu Cheng; Kelin Sun; Xiangyang Liu; Dekang Fang; Junqiang Chen; Zefen Xiao
Journal:  Ann Surg Oncol       Date:  2019-06-10       Impact factor: 5.344

Review 6.  Esophageal cancer: Risk factors, genetic association, and treatment.

Authors:  Fang-Liang Huang; Sheng-Jie Yu
Journal:  Asian J Surg       Date:  2016-12-13       Impact factor: 2.767

7.  Circle RNA hsa_circRNA_100290 serves as a ceRNA for miR-378a to regulate oral squamous cell carcinoma cells growth via Glucose transporter-1 (GLUT1) and glycolysis.

Authors:  Xing Chen; Jianjun Yu; Hao Tian; Zhenfeng Shan; Wei Liu; Zhen Pan; Jihao Ren
Journal:  J Cell Physiol       Date:  2019-06-11       Impact factor: 6.384

Review 8.  Screening for esophageal squamous cell carcinoma: recent advances.

Authors:  Don C Codipilly; Yi Qin; Sanford M Dawsey; John Kisiel; Mark Topazian; David Ahlquist; Prasad G Iyer
Journal:  Gastrointest Endosc       Date:  2018-04-27       Impact factor: 9.427

9.  CircRNA circ_POLA2 promotes lung cancer cell stemness via regulating the miR-326/GNB1 axis.

Authors:  Zhaohui Fan; Yongkang Bai; Qian Zhang; Pudong Qian
Journal:  Environ Toxicol       Date:  2020-06-08       Impact factor: 4.119

10.  MicroRNA-338-5p reverses chemoresistance and inhibits invasion of esophageal squamous cell carcinoma cells by targeting Id-1.

Authors:  Liang Han; Di Cui; Bin Li; Wen Wen Xu; Alfred King Y Lam; Kin Tak Chan; Yun Zhu; Nikki P Y Lee; Simon Y K Law; Xin Yuan Guan; Yan Ru Qin; Kwok Wah Chan; Stephanie Ma; Sai Wah Tsao; Annie L M Cheung
Journal:  Cancer Sci       Date:  2019-11-17       Impact factor: 6.716

View more
  2 in total

1.  Circ_0000705 facilitates proline metabolism of esophageal squamous cell carcinoma cells by targeting miR-621/PYCR1 axis.

Authors:  Cui-Juan Qian; Yi-Yang Tong; Lin-Ken Wu; Yi-Chao Wang; Xiao-Sheng Teng; Jun Yao
Journal:  Discov Oncol       Date:  2022-06-22

Review 2.  Current advances and future perspectives on the functional roles and clinical implications of circular RNAs in esophageal squamous cell carcinoma: more influential than expected.

Authors:  Chenxi Ju; Jing He; Chang Wang; Jinxiu Sheng; Jinlin Jia; Dan Du; Hongle Li; Mingxia Zhou; Fucheng He
Journal:  Biomark Res       Date:  2022-06-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.